Janux Therapeutics jumps 12% on $850M cancer pact With Bristol Myers
Janux Therapeutics (NASDAQ:JANX) shares surged as much as 12% in early trading Thursday following the announcement of a global licensing deal with Bristol Myers Squibb (NYSE:BMY) worth up to $850 million.























